C54.9 Malignant neoplasm of corpus uteri, unspecified

Name of the Condition

• Malignant neoplasm of corpus uteri, unspecified (C54.9)
• Also known as unspecified uterine corpus cancer.

Summary

Malignant neoplasm of the corpus uteri, unspecified, refers to cancer originating in the body of the uterus (excluding the cervix) where the specific site within the corpus is not documented. This condition is a subset of uterine cancer and may involve the endometrial lining or muscular layer. It often presents with abnormal bleeding or pelvic symptoms, though the exact location is not specified in the diagnosis.

Causes

The exact causes are not fully understood, but hormonal imbalances—particularly excess estrogen without progesterone—are strongly implicated. Genetic mutations, environmental exposures, and prior medical conditions may also contribute to its development.

Risk Factors

• Advanced age, especially postmenopausal women.
• Obesity, which increases estrogen levels.
• Estrogen-only hormone replacement therapy.
• Family history of uterine, ovarian, or colorectal cancer.
• Conditions like polycystic ovary syndrome (PCOS) or endometrial hyperplasia.
• Prior radiation therapy to the pelvic region.

Symptoms

• Abnormal vaginal bleeding (e.g., postmenopausal bleeding or heavy menstrual periods).
• Pelvic pain or pressure.
• Unusual vaginal discharge, which may be watery or blood-tinged.
• Pain during intercourse.
• Unexplained weight loss or fatigue in advanced cases.

Diagnosis

Diagnosis typically involves a pelvic examination, transvaginal ultrasound to visualize uterine abnormalities, and endometrial biopsy to assess tissue samples. Hysteroscopy may be used to examine the uterine cavity directly. Imaging studies like MRI or CT scans may help evaluate the extent of the disease.

Treatment Options

Treatment depends on the cancer’s stage, grade, and patient health. Options include surgery (e.g., hysterectomy), radiation therapy, chemotherapy, and hormone therapy. The specific approach is tailored to the individual case.

Prognosis and Follow-Up

Prognosis varies based on the cancer’s stage, grade, and response to treatment. Early-stage cancers generally have better outcomes. Follow-up care includes regular pelvic exams, imaging, and monitoring for recurrence. Long-term surveillance is recommended to detect any new or recurring disease.

Complications

Potential complications include metastasis to other organs, treatment-related side effects (e.g., infertility, bowel or bladder issues), and recurrence. Advanced disease may lead to severe pain, anemia from bleeding, or organ dysfunction.

Lifestyle & Prevention

Maintaining a healthy weight, managing hormonal imbalances, and avoiding unopposed estrogen therapy may reduce risk. Regular screenings and prompt evaluation of abnormal bleeding are important for early detection.

When to Seek Professional Help

Seek medical attention for abnormal vaginal bleeding, persistent pelvic pain, or unusual discharge. Early evaluation is critical for timely diagnosis and treatment.

Tips for Medical Coders

Document the specific site within the corpus uteri when possible to support more precise coding. If the site is unspecified, use C54.9. Ensure clinical documentation aligns with the diagnosis to justify the code selection.